The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
ORGANIZATION
JGA Vows Strict Response to Choseido’s Biz Suspension Order
The Japan Generic Medicines Association (JGA) said on October 11 that it will take a strict response to a business suspension order issued the same day to its member company Choseido Pharmaceutical over its manufacturing issues. “This severe administrative penalty…
To read the full story
Related Article
- Choseido Resumes Operations after 31-Day Biz Suspension
November 12, 2021
- Choseido Revamps Management, Sacks President Harada over GMP Violations
October 26, 2021
- Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
- Lack of Management Response, Tight Manufacturing Plans to Blame in Choseido Issue: Report
October 12, 2021
- Choseido Woes Cast Clouds on Generic Inroads in Tokushima, Worst Player in Penetration
October 12, 2021
- Choseido Hit by Biz Suspension of Up to 31 Days over Manufacturing Flaws
October 11, 2021
ORGANIZATION
- Over 20% of All Generics under Restricted Shipments: FPMAJ
March 14, 2023
- PhRMA Unveils Proposal for FY2024 Reform, Says This Year Is “Turning Point” to Improve Access
March 10, 2023
- Labor Unions Prod MHLW to Renew Efforts to Improve Compliance with Drug Distribution Guidelines
March 3, 2023
- OB/GYN Group Urges MHLW to Facilitate Access to Oral Abortion Drug
February 24, 2023
- Policy Veterans’ Group Floats Proposal to Prevent Unprofitability to Stabilize Drug Supply
February 21, 2023
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…